PURPOSE: The aim of the study was to investigate the pathophysiology of oxaliplatin-induced neurotoxicity using clinical nerve excitability techniques that provide information about axonal ion channel function. EXPERIMENTAL DESIGN: Excitability studies were combined with standard nerve conduction studies and clinical assessment in 22 patients undergoing treatment with oxaliplatin. RESULTS: Excitability studies recorded before and immediately after oxaliplatin infusion for 89 treatment cycles revealed significant increases in refractoriness and relative refractory period postinfusion in all patients, consistent with an effect of oxaliplatin on axonal Na(+) channels. However, those patients that developed chronic neuropathy had significantly greater changes. Following cessation of oxaliplatin treatment, 41% of patients had persistent symptoms and nerve conduction abnormalities consistent with the development of chronic neuropathy. CONCLUSION: The present study provides evidence that oxaliplatin-induced neurotoxicity is mediated through an effect on axonal Na(+) channels. Clinical nerve excitability techniques may prove beneficial in monitoring for early signs of neurotoxicity and in the assessment of future prophylactic therapies.
PURPOSE: The aim of the study was to investigate the pathophysiology of oxaliplatin-induced neurotoxicity using clinical nerve excitability techniques that provide information about axonal ion channel function. EXPERIMENTAL DESIGN: Excitability studies were combined with standard nerve conduction studies and clinical assessment in 22 patients undergoing treatment with oxaliplatin. RESULTS: Excitability studies recorded before and immediately after oxaliplatin infusion for 89 treatment cycles revealed significant increases in refractoriness and relative refractory period postinfusion in all patients, consistent with an effect of oxaliplatin on axonal Na(+) channels. However, those patients that developed chronic neuropathy had significantly greater changes. Following cessation of oxaliplatin treatment, 41% of patients had persistent symptoms and nerve conduction abnormalities consistent with the development of chronic neuropathy. CONCLUSION: The present study provides evidence that oxaliplatin-induced neurotoxicity is mediated through an effect on axonal Na(+) channels. Clinical nerve excitability techniques may prove beneficial in monitoring for early signs of neurotoxicity and in the assessment of future prophylactic therapies.
Authors: Jacob A Vincent; Krystyna B Wieczerzak; Hanna M Gabriel; Paul Nardelli; Mark M Rich; Timothy C Cope Journal: Neurobiol Dis Date: 2016-07-07 Impact factor: 5.996
Authors: Michael A Gordon; Wu Zhang; Dongyun Yang; Syma Iqbal; Anthony El-Khouiery; Fumio Nagashima; Georg Lurje; Melissa Labonte; Peter Wilson; Andy Sherrod; Robert D Ladner; Heinz-Josef Lenz Journal: Pharmacogenomics Date: 2011-01 Impact factor: 2.533
Authors: Jennifer R Deuis; Yu Ling Lim; Silmara Rodrigues de Sousa; Richard J Lewis; Paul F Alewood; Peter J Cabot; Irina Vetter Journal: Neuro Oncol Date: 2014-04-08 Impact factor: 12.300
Authors: Susanna B Park; Cindy S Y Lin; Arun V Krishnan; David Goldstein; Michael L Friedlander; Matthew C Kiernan Journal: Oncologist Date: 2011-04-08
Authors: Sunita Padman; Jaein Lee; Rajiv Kumar; Mark Slee; Paul Hakendorf; Alison Richards; Bogda Koczwara; Ganessan Kichenadasse; Shawgi Sukumaran; Amitesh Roy; Sina Vatandoust; Christos S Karapetis Journal: Support Care Cancer Date: 2014-09-16 Impact factor: 3.603